Last reviewed · How we verify
Dexamfetamine sulphate
Dexamfetamine sulphate is a central nervous system stimulant that increases the release and blocks the reuptake of dopamine and norepinephrine in the brain.
Dexamfetamine sulphate is a central nervous system stimulant that increases the release and blocks the reuptake of dopamine and norepinephrine in the brain. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Dexamfetamine sulphate |
|---|---|
| Also known as | Magisterial Dexamfetamine, Tentin |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Sympathomimetic amine; CNS stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Dexamfetamine is the active d-isomer of amphetamine that enhances catecholaminergic neurotransmission by stimulating the release of dopamine and norepinephrine from presynaptic terminals and inhibiting their reuptake via monoamine transporters. This results in increased synaptic concentrations of these neurotransmitters, leading to enhanced alertness, focus, and motor activity. It is commonly used in the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Tachycardia
- Anxiety
- Headache
- Tremor
Key clinical trials
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression (PHASE2)
- The Day-time Response Variation of (Lis)Dexamphetamine
- FASST - Fetal Alcohol Spectrum Stimulant Trial (PHASE4)
- Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis (PHASE2)
- Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (PHASE1)
- Safety of SPD465 in Treating Adults With ADHD. (PHASE3)
- A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamfetamine sulphate CI brief — competitive landscape report
- Dexamfetamine sulphate updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI